Magnolia NeuroSciences

company

About

Magnolia NeuroSciences discovers and develops drug-like small molecule therapeutics for the prevention of neuronal cell death.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$31M
Industries
Biotechnology,Health Care,Neuroscience,Wellness
Founded date
Jan 1, 2018
Number Of Employee
1 - 10
Operating Status
Active

Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$31M
Magnolia NeuroSciences has raised a total of $31M in funding over 2 rounds. Their latest funding was raised on Aug 13, 2018 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 13, 2018 Series A $31M 3 Detail

Investors

Number of Lead Investors
Number of Investors
3
Magnolia NeuroSciences is funded by 3 investors. ARCH Venture Partners and Watson Fund are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series A
Watson Fund Series A
Lilly Asia Ventures Series A